Curaleaf Holdings (CSE: CURA) announced this afternoon that it has received approval for five adult use licenses in its home state of Massachusetts. Three of the licenses are final licenses, while two are considered provisional.
Of the five licenses granted in total, three are for the co-location of adult-use activities at currently licensed medical properties. One final license is for adult use sales at a currently medical-only dispensary in Oxford, Mass, while the two other final licenses are for adult-use cultivation and manufacturing at a currently operational facility in Webster, Mass.
The two provisional licenses are for retail locations in Provincetown, and Ware. Hanover appears to be the only medical dispensary which will not presently be licensed for adult-use products.
The final adult-use licenses will still require “Post final” inspections, as well as “Commence Operations” inspections, which are expected to occur in the coming months as per the company news release.
Curaleaf Holdings is currently trading at $10.17, up 3.67% on todays news that Cowen & Company had assigned the firm a price target of US$10.50 and a rating of outperform while initiating coverage on the company.
Information for this briefing was found via Curaleaf Holdings. The author has no securities or affiliations related to the discussed organizations. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
US Cannabis, Momentum, With Lots of Hurdles
The US Cannabis market has been a confusing ride for investors to comprehend. We have...